Pertussis Market Overview: Trends, Treatments, and Future Outlook

The Pertussis Market is poised for steady growth, fueled by rising awareness of the disease and advancements in effective interventions. Also known as whooping cough, pertussis is a severe respiratory infection caused by Bordetella pertussis, progressing through catarrhal, paroxysmal, and convalescent stages. Accurate diagnosis often relies on techniques such as culture, PCR, and paired sera tests, with the latter considered the most reliable.

Growing Importance of Pertussis Therapeutics

Vaccination remains the cornerstone of Pertussis treatment and prevention. In the United States, DTaP and Tdap vaccines are widely administered, ensuring all adolescents and adults receive at least three doses. Treatment primarily involves macrolide antibiotics like erythromycin, clarithromycin, or azithromycin, complemented by supportive care such as hydration, oxygen therapy, and avoiding respiratory irritants.

The Pertussis Therapeutics Market has expanded with new vaccines and innovative delivery methods. Key players in the Pertussis Drugs Market include Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, and BioNet. Emerging vaccines like BPZE1, an intranasal booster from ILiAD Biotechnologies, and Mitsubishi Tanabe Pharma’s 5-in-1 BK1310/MT-2355 vaccine are expected to reshape market dynamics.

Epidemiology and Market Size

According to DelveInsight’s report, approximately 19 million individuals were vaccinated in the U.S. in 2022, including 5 million adults receiving booster doses. Across the seven major markets (7MM), around 34 million people were vaccinated in 2022, a number anticipated to rise due to enhanced awareness, updated immunization guidelines, and new vaccine development. The Pertussis Treatment Market Size in the 7MM was valued at $3.5 billion in 2022, with the U.S. representing the largest share.

Vaccine Landscape and Market Dynamics

Key vaccines driving the Pertussis Market include:

ADACEL (Sanofi Pasteur): A trivalent booster for pertussis, tetanus, and diphtheria, available in 55 countries.
BOOSTRIX (GSK): Recommended for individuals aged 10 and above, including maternal immunization programs.

Emerging therapies and pipeline innovations are critical to expanding the Pertussis Therapeutics Market. Adult booster compliance remains relatively low, creating opportunities for novel interventions, while infant and childhood vaccination rates remain high across the 7MM.

Competitive Landscape and Insights

The Pertussis Companies landscape is competitive, especially in the U.S. and Europe, with vaccines such as PEDIARIX, PENTACEL, and Vaxelis influencing market dynamics. In Japan, Mitsubishi leads with TETRABIK. Market analysis covers adoption rates, sales performance, market share, pipeline development, collaborations, patent filings, and regulatory progress.